论文部分内容阅读
目的:分析瑞格列奈治疗2型糖尿病的临床效果。方法:选择2013年1月-2014年12月我院门诊2型糖尿病患者68例,随机分成两组,对照组使用二甲双胍,观察组使用瑞格列奈,观察两组患者的治疗效果。结果:观察组显效率、副作用发生率分别为:55.88%、2.94%,对照组为:32.35%、8.82%,经统计学比较(P<0.05),具有显著差异性。结论:瑞格列奈治疗2型糖尿病具有良好的临床效果,且副作用少,用药安全,值得在基层医院推广使用。
Objective: To analyze the clinical effect of repaglinide on type 2 diabetes mellitus. Methods: From January 2013 to December 2014, 68 outpatients with type 2 diabetes mellitus were randomly divided into two groups. Metformin was used in the control group and repaglinide was used in the observation group. The therapeutic effect was observed in both groups. Results: The rates of obvious and side effects in the observation group were 55.88% and 2.94% respectively, and those in the control group were 32.35% and 8.82% respectively. There was significant difference between the two groups (P <0.05). Conclusion: Repaglinide is effective in treating type 2 diabetes mellitus with less side effects and medication safety, which is worth popularizing in primary hospitals.